Mokari Atabak
Chief Financial Officer
Mokari Atabak has filed 8 SEC Form 4 filings (42 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Sep 4, 2026.
On the most recent filing, Mokari Atabak is listed as Chief Financial Officer at CORCEPT THERAPEUTICS INC. Inside the rolling window, Mokari Atabak reported no open-market purchases and 4 open-market sales totaling $18.7M in CORT. The largest disclosed transaction in the window is a sale of 80,000 CORT shares on Jul 30, 2026, worth $9.2M.
Companies traded
Other insiders at CORT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$18.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Mokari Atabak made?
Mokari Atabak has filed 8 SEC Form 4 filings (42 transaction rows) across 1 company since 2025.
Which companies does Mokari Atabak trade?
Mokari Atabak has filed SEC Form 4 disclosures for 1 company, including CORT.
When was Mokari Atabak's most recent SEC Form 4 filing?
Mokari Atabak's most recent SEC Form 4 filing on Tracefour is dated Sep 4, 2026.
What is Mokari Atabak's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Mokari Atabak is listed as Chief Financial Officer.
What is Mokari Atabak's total buy and sell value in the current window?
Inside the rolling retention window, Mokari Atabak bought $0 and sold $18.7M based on SEC Form 4 filings.
What was Mokari Atabak's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 80,000 CORT shares on 2026-07-30, worth $9.2M, per SEC Form 4 filings.